Copyright
©2010 Baishideng Publishing Group Co.
World J Radiol. Nov 28, 2010; 2(11): 427-433
Published online Nov 28, 2010. doi: 10.4329/wjr.v2.i11.427
Published online Nov 28, 2010. doi: 10.4329/wjr.v2.i11.427
Name | Acronym | Gd-DTPA | Gd-EOB-DTPA | Gd-BOPTA | MS325 | Gd-DTPA-BMA | Gd-DTPA-BMEA | Gd-HP-DO3A | Gd-BT-DO3A | Gd-DOTA |
Generic name | Gadopentetate dimeglumine | Gadoxetic acid, disodium salt | Gadobenate dimeglumine | Gadofosveset, trisodium salt | Gadodiamide | Gadoversetamide | Gadoteridol | Gadobutrol | Gadoterate meglumine | |
Trade name | Magnevistâ | Primovist® | MultiHanceâ | Vasovist® | Omniscanâ | OptiMARKâ | ProHanceâ | Gadovistâ | Dotaremâ | |
Company | Bayer-Schering | Bayer-Schering | Bracco | EPIX | GE-Healthcare | Mallinckrodt | Bracco | Bayer-Schering | Guerbet | |
Chemical structure | Open-chain | Open-chain | Open-chain | Open-chain | Open-chain | Open-chain | Macrocyclic | Macrocyclic | Macrocyclic | |
Charge | Ionic | Ionic | Ionic | Ionic | Nonionic | Nonionic | Nonionic | Nonionic | Ionic | |
Concentration (M) | 0.5 | 0.25 | 0.5 | 0.25 | 0.5 | 0.5 | 0.5 | 1 | 0.5 | |
Osmolality at 37°C (mOsm/kg H2O) | 1960 | 688 | 1970 | 825 | 789 | 1110 | 630 | 1603 | 1350 | |
Viscosity (mPa.s) at 37°C | 2.9 | 1.19 | 5.3 | 2.06 | 1.4 | 2 | 1.3 | 4.96 | 2 | |
Formulation | Free DTPA (1 mmol/L) | Ca-EOB-DTPA (trisodium salt) (1.5 mmol/L) | No formulation | Fosveset (0.325 mmol/L) | Ca-DTPA-BMA (caldiamide) (Na+ salt) (25 mmol/L) | Ca-DTPA-BMEA (Na+ salt) (50 mmol/L) | [Ca-HP-DO3A]2 (Ca2+ salt) (0.5 mmol/L) | Ca-BT-DO3A (Na+ salt) (1.0 mmol/L) | No formulation | |
Hydrophilicity (log P Butanol/water) | -3.16 | -2.11 | -2.33 | -2.11 | -2.13 | N/A | -1.98 | -2 | -2.87 | |
log Ktherm | 22.1 | 23.5 | 22.6 | 22.06 | 16.9 | 16.6 | 23.8 | 21.8 | 25.6 | |
log Kcond | 17.7 | 18.7 | 18.4 | 18.9 | 14.9 | 15 | 17.1 | 14.7 | 19.3 | |
Kinetic Stabilitya | Low | Medium | Medium | Medium | Low | Low | High | High | High |
Gd-CA | T1/2, pH 1.2 | T1/2, pH 1 | T1/2, pH 1 | T1/2, pH 1 (Temp 250) |
Temperature (°C) | 370 | 370 | 250 | |
Dotaremâ (Guerbet, France) | 85 h | 23 h | 338 h | 338 h |
Gadovistâ (Bayer Schering Pharma AG, Germany) | 18 h | 7 h | 43 h | 43 h |
ProHanceâ (Bracco, Italy) | 4 h | 1.6 h | 3.9 h | 3.9 h |
All linear chelates | ND | ND | < 5 s | < 5 s |
- Citation: Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. World J Radiol 2010; 2(11): 427-433
- URL: https://www.wjgnet.com/1949-8470/full/v2/i11/427.htm
- DOI: https://dx.doi.org/10.4329/wjr.v2.i11.427